Celcuity (CELC) vs GRAIL (GRAL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GRAIL (GRAL) has outperformed Celcuity (CELC) over the past year, gaining 111.6% versus a gain of 33.7%. GRAIL is the larger company by market cap ($5.94 billion vs $3.22 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | GRAL |
|---|---|---|
| Share price | $65.78 | $132.90 |
| Market cap | $3.22B | $5.94B |
| 1-day change | -7.68% | -3.19% |
| YTD return | -34.05% | +55.28% |
| 1-year return | +33.66% | +111.56% |
| 5-year return | +261.43% | — |
| EPS (TTM) | $-4.31 | $-9.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $147.17M |
| Revenue growth (YoY) | — | +17.18% |
| Net income (latest FY) | $-177.04M | $-408.35M |
| Operating margin | — | -381.98% |
| Net margin | — | -277.47% |
| 52-week high | $151.02 | $166.48 |
| 52-week low | $45.03 | $41.50 |
| Distance from 52-week high | -56.44% | -20.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +138.54% | -15.43% |
| Average volume | 1.18M | 930.77K |
| Shares outstanding | 48.93M | 44.67M |
| Employees | 155 | 910 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRAL has outperformed CELC by 77.9 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
CELC vs GRAL FAQ
Which is bigger, Celcuity or GRAIL?
GRAIL (GRAL) is larger, with a market capitalization of $5.94B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or GRAL?
GRAL returned +111.56% over the past 12 months, compared with +33.66% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and GRAIL in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.